Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China.
Aurinia Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$16.76|
|52 Week High||CA$11.77|
|52 Week Low||CA$26.00|
|1 Month Change||17.29%|
|3 Month Change||-2.27%|
|1 Year Change||-8.86%|
|3 Year Change||125.88%|
|5 Year Change||554.69%|
|Change since IPO||-69.53%|
Recent News & Updates
Companies Like Aurinia Pharmaceuticals (TSE:AUP) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|AUP||CA Biotechs||CA Market|
Return vs Industry: AUP underperformed the Canadian Biotechnology industry which returned -1.4% over the past year.
Return vs Market: AUP underperformed the Canadian Market which returned 25.7% over the past year.
Stable Share Price: AUP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: AUP's weekly volatility (10%) has been stable over the past year.
About the Company
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
Aurinia Pharmaceuticals Fundamentals Summary
|AUP fundamental statistics|
Is AUP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AUP income statement (TTM)|
|Cost of Revenue||US$45.70m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.17|
|Net Profit Margin||-256.27%|
How did AUP perform over the long term?See historical performance and comparison
Is Aurinia Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AUP (CA$16.76) is trading below our estimate of fair value (CA$173.61)
Significantly Below Fair Value: AUP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AUP is unprofitable, so we can't compare its PE Ratio to the North American Biotechnology industry average.
PE vs Market: AUP is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AUP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AUP is overvalued based on its PB Ratio (5.1x) compared to the CA Biotechnology industry average (3.5x).
How is Aurinia Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: AUP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AUP's is expected to become profitable in the next 3 years.
Revenue vs Market: AUP's revenue (53.8% per year) is forecast to grow faster than the Canadian market (4.8% per year).
High Growth Revenue: AUP's revenue (53.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AUP's Return on Equity is forecast to be high in 3 years time (31%)
How has Aurinia Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AUP is currently unprofitable.
Growing Profit Margin: AUP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AUP is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.
Accelerating Growth: Unable to compare AUP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AUP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechnology industry (0.1%).
Return on Equity
High ROE: AUP has a negative Return on Equity (-44.42%), as it is currently unprofitable.
How is Aurinia Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AUP's short term assets ($349.7M) exceed its short term liabilities ($29.3M).
Long Term Liabilities: AUP's short term assets ($349.7M) exceed its long term liabilities ($24.7M).
Debt to Equity History and Analysis
Debt Level: AUP is debt free.
Reducing Debt: AUP has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AUP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AUP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AUP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AUP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AUP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AUP's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Peter Greenleaf (51 yo)
Mr. Peter S. Greenleaf, M.B.A., has been President, Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019. Mr. Greenleaf has been a Director at Antares Pharma, Inc. sinc...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD10.68M) is above average for companies of similar size in the Canadian market ($USD2.04M).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
Experienced Management: AUP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: AUP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AUP insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Aurinia Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Aurinia Pharmaceuticals Inc.
- Ticker: AUP
- Exchange: TSX
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.152b
- Shares outstanding: 128.40m
- Website: https://www.auriniapharma.com
Number of Employees
- Aurinia Pharmaceuticals Inc.
- 4464 Markham Street
- Suite 1203
- British Columbia
- V8Z 7X8
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/24 22:10|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.